{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:03:22Z","timestamp":1790391802133,"version":"4.1.0"},"reference-count":30,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2021,8,9]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>Dilated cardiomyopathy (DCM) is a heterogenous group of disorders characterised by left ventricular dilatation and dysfunction, in the absence of factors affecting loading conditions such as hypertension or valvular disease, or significant coronary artery disease. The prevalence of idiopathic DCM is estimated between 1:250 and 1:500 individuals. Determining the aetiology of DCM can be challenging, particularly when evaluating an individual and index case with no classical history or investigations pointing towards an obvious acquired cause, or no clinical clues in the family history to suggest a genetic cause. We present a family affected by DCM associated with Filamin C variant, causing sudden cardiac death at a young age and heart failure due to severe left ventricular impairment and myocardial scarring. We review the diagnosis and treatment of DCM, its genetic associations and potential acquired causes. Thorough assessment is mandatory to risk stratify and identify patients who may benefit from primary prevention implantable cardioverter defibrillator therapy according to international guidelines. Genetic testing has some limitations, and is positive in only 20%\u201335% of DCM, but should be considered in specific cases to identify families who may benefit from cascade screening after appropriate counselling. The management of often complex familial cardiomyopathy requires specialist input for every case, and the appropriate infrastructure to coordinate investigations.<\/jats:p>","DOI":"10.1136\/heartjnl-2021-319682","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T13:52:08Z","timestamp":1629467528000},"page":"676-682","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Dilated cardiomyopathy: the role of genetics, highlighted in a family with Filamin C (FLNC) variant"],"prefix":"10.1136","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6086-6813","authenticated-orcid":false,"given":"Jason N","family":"Dungu","sequence":"first","affiliation":[{"name":"Cardiology, Essex Cardiothoracic Centre, Mid & South Essex NHS Foundation Trust, Basildon, UK"},{"name":"Circulatory Health Research Group, Anglia Ruskin University, Chelmsford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha G","family":"Langley","sequence":"additional","affiliation":[{"name":"Cardiology, Essex Cardiothoracic Centre, Mid & South Essex NHS Foundation Trust, Basildon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Hardy-Wallace","sequence":"additional","affiliation":[{"name":"Cardiology, Essex Cardiothoracic Centre, Mid & South Essex NHS Foundation Trust, Basildon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Li","sequence":"additional","affiliation":[{"name":"Cardiology, Essex Cardiothoracic Centre, Mid & South Essex NHS Foundation Trust, Basildon, UK"},{"name":"Circulatory Health Research Group, Anglia Ruskin University, Chelmsford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella M","family":"Barbagallo","sequence":"additional","affiliation":[{"name":"Cardiology, Essex Cardiothoracic Centre, Mid & South Essex NHS Foundation Trust, Basildon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Field","sequence":"additional","affiliation":[{"name":"Cardiology, Essex Cardiothoracic Centre, Mid & South Essex NHS Foundation Trust, Basildon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Homfray","sequence":"additional","affiliation":[{"name":"Royal Brompton & Harefield NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Oluwasefunmi","family":"Savage","sequence":"additional","affiliation":[{"name":"Cardiology, Essex Cardiothoracic Centre, Mid & South Essex NHS Foundation Trust, Basildon, UK"},{"name":"Circulatory Health Research Group, Anglia Ruskin University, Chelmsford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"2025091922353086000_108.9.676.1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI62862"},{"key":"2025091922353086000_108.9.676.2","first-page":"1","article-title":"Clinical CMR: one-year case mix, outcomes and stress-testing accuracy from a regional tertiary centre","volume":"26","author":"Chaudhury","year":"2019","journal-title":"Br J Cardiol"},{"key":"2025091922353086000_108.9.676.3","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-020-01423-w","article-title":"Clinical implications of the genetic architecture of dilated cardiomyopathy","volume":"22","author":"Wilsbacher","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"2025091922353086000_108.9.676.4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.113.300282"},{"key":"2025091922353086000_108.9.676.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.590"},{"key":"2025091922353086000_108.9.676.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2013.105"},{"key":"2025091922353086000_108.9.676.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.06.072"},{"key":"2025091922353086000_108.9.676.8","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/humu.24004","article-title":"A mutation update for the FLNc gene in myopathies and cardiomyopathies","volume":"41","author":"Verdonschot","year":"2020","journal-title":"Hum Mutat"},{"key":"2025091922353086000_108.9.676.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2017.12.003"},{"key":"2025091922353086000_108.9.676.10","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1016\/j.hrthm.2019.09.019","article-title":"2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary","volume":"16","author":"Towbin","year":"2019","journal-title":"Heart Rhythm"},{"key":"2025091922353086000_108.9.676.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110186"},{"key":"2025091922353086000_108.9.676.12","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3719"},{"key":"2025091922353086000_108.9.676.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.03.530"},{"key":"2025091922353086000_108.9.676.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc052632"},{"key":"2025091922353086000_108.9.676.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.08.078"},{"key":"2025091922353086000_108.9.676.16","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1161\/CIRCULATIONAHA.119.044934","article-title":"Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy","volume":"141","author":"Smith","year":"2020","journal-title":"Circulation"},{"key":"2025091922353086000_108.9.676.17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.646778"},{"key":"2025091922353086000_108.9.676.18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.hrcr.2020.05.004","article-title":"Emerging role of genetic analysis for stratification of sudden cardiac death risk in dilated cardiomyopathy: an illustrative case","volume":"6","author":"Yao","year":"2020","journal-title":"HeartRhythm Case Rep"},{"key":"2025091922353086000_108.9.676.19","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs119"},{"key":"2025091922353086000_108.9.676.20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.hlc.2019.10.014","article-title":"Genetic testing in inherited heart diseases","volume":"29","author":"Ingles","year":"2020","journal-title":"Heart Lung Circ"},{"key":"2025091922353086000_108.9.676.21","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"2016","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2025091922353086000_108.9.676.22","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"Sglt2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"2025091922353086000_108.9.676.23","first-page":"746","article-title":"ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"2015","author":"Priori","year":"2015","journal-title":"Eur Heart J"},{"key":"2025091922353086000_108.9.676.24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.21037\/cdt.2017.06.06","article-title":"Implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a meta-analysis of randomized controlled trials","volume":"7","author":"Masri","year":"2017","journal-title":"Cardiovasc Diagn Ther"},{"key":"2025091922353086000_108.9.676.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2016.09.017"},{"key":"2025091922353086000_108.9.676.26","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1161\/CIRCULATIONAHA.120.048477","article-title":"Relationship of LVEF and myocardial scar to long-term mortality risk and mode of death in patients with nonischemic cardiomyopathy","volume":"143","author":"Klem","year":"2021","journal-title":"Circulation"},{"key":"2025091922353086000_108.9.676.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32484-X"},{"key":"2025091922353086000_108.9.676.28","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2011-300048"},{"key":"2025091922353086000_108.9.676.29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.mehy.2019.05.013","article-title":"Crispr\/Cas 9 system for the treatment of dilated cardiomyopathy: a hypothesis related to function of a MAP kinase","volume":"128","author":"Olivaes","year":"2019","journal-title":"Med Hypotheses"},{"key":"2025091922353086000_108.9.676.30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.120.053033","article-title":"Evidence-based assessment of genes in dilated cardiomyopathy","volume":"144","author":"Jordan","year":"2021","journal-title":"Circulation"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2021-319682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T05:35:39Z","timestamp":1758346539000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2021-319682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,4,8]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/heartjnl-2021-319682"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2021-319682","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]}}}